| Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB) (NCT05081401) | Huashan Hospital | 2022-05-23 |
| Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial (NCT05017324) | Universiteit Antwerpen | 2021-09-21 |
| Novel Triple-dose Tuberculosis Retreatment Regimen (NCT04260477) | Institute of Tropical Medicine, Belgium | 2021-03-01 |
| Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS (NCT04717908) | Huashan Hospital | 2021-01-20 |
| MDR-TB Close Contacts Tracing in China (TCCT Study) (NCT04484129) | Huashan Hospital | 2020-07-21 |
| Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China (NCT04421495) | Beijing Chest Hospital | 2020-07-16 |
| Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (NCT03867136) | Huashan Hospital | 2020-06-01 |
| Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial (NCT03942354) | Medecins Sans Frontieres, Netherlands | 2019-09-01 |
| NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB (NCT03604848) | Huashan Hospital | 2018-08-05 |
| An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis (NCT02454205) | University of Cape Town | 2015-11-12 |
| Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment (NCT02727582) | University of Cape Town | 2015-07-30 |
| Line Probe Assay Evaluation Study (NCT02984579) | Foundation for Innovative New Diagnostics, Switzerland | 2015-03-01 |
| Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide (NCT02120638) | Huashan Hospital | 2014-04-01 |
| Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan (NCT02496572) | Medecins Sans Frontieres, Netherlands | 2013-09-01 |
| A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB) (NCT01859923) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2013-07-20 |
| Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis (NCT01856634) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2013-06-14 |
| Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients (NCT01521364) | University Medical Center Groningen | 2011-12-01 |
| Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis (NCT01424670) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2011-09-02 |
| Linezolid to Treat Extensively-Drug Resistant Tuberculosis (NCT00727844) | National Institute of Allergy and Infectious Diseases (NIAID) | 2008-07-01 |